- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04821765
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
March 26, 2021 updated by: Wang Xin, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase II Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Squamous Cell Carcinoma
Chemoradiotherapy(CRT) is the main treatment for esophageal cancer patients with recurrent desease,and checkpoint blockade (PD-1) have been shown to be effective in advanced esophageal cancer.
Therefore, PD-1 combined with chemoradiotherapy (CRT)may further improve the efficacy and become a new method for the treatment of esophageal cancer.This study intends to conduct a single-arm, prospective clinical study, aiming to evaluate the safety and efficacy of PD-1 combined with chemoradiotherapy(CRT) in patients with oligometastatic esophageal squamous cell carcinoma.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
35
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
-
Contact:
- Xin Wang, MD
- Email: beryl_wx2000@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
•≥18 years;
- Esophageal squamous cell carcinomas;
- After radical treatment including surgery or definitive chemoradiotherapy
- Definition of oligometastases:≤3 metastases, including tumor beds and recurrent anastomotic sites;regional lymph node is defined as one metastatic site(AJCC8th, supraclavicular, mediastinal, abdominal);metastases lesion in liver, lung, bone and brain is no more than 1.
- Karnofsky performance status(KPS)≥ 70;
- No immunotherapy were performed after recurrence;
- a white-cell count of at least 3500G/L, a hemoglobin concentration of at least 100 g/L, a platelet count of at least 100,000/lL, aspartate aminotransferase and alanine aminotransferase levels of within 1.5 times the upper limit of normal, a serum bilirubin level of 1.5 mg/dL or less, a creatinine level of 1.1 mg/dL or less;
- Hepatitis virus indicators: normal or hepatitis virus DNA titer less than 500 at the same time in an infectious disease hospital, and with the consent of the doctor can be treated;
Exclusion Criteria:
- Pregnancy, possible pregnancy, or breast-feeding;
- Psychological, family, social and other factors lead to uninformed consent;
- An esophageal mediastinal fistula and/or an esophageal tracheal fistula prior to treatment;
- Serious complications such as ischemic heart disease, arrhythmias, or other types of heart disease requiring treatment; liver cirrhosis; interstitial pneumonia or pulmonary fibrosis; active gastrointestinal bleeding; mental disorders being treated with antipsychoticagents or requiring treatment;
- Controlled diabetes mellitus;
- A history of autoimmune disease, autoimmune disease (such as colitis, hepatitis, hyperthyroidism, including but not limited to these disease or syndrome) and a history of immune deficiency, including test positive for HIV, or has other acquired, congenital immunodeficiency disease, or have a history of organ transplantation and the history of allogeneic bone marrow transplantation;
- A history of interstitial lung disease and a history of non-infectious pneumonia;
- Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 Copies /mL), hepatitis C ;(positive HCV antibody and HCV-RNA above the detection threshold of the assay)
- Any situation that is unstable or may compromise patient safety and compliance ;
- Active infections, such as active tuberculosis, are present;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemoradiotherapy Combined With PD-1 Antibody
The arm received chemoradiotherapy, 50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week) to recurrent sites combined with chemotherapy(Cisplatin 75 mg/m2/day 1, and albumin paclitaxel 150 mg/m2/day 1 , every 3 weeks, 2 cycles ).PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg,d1,every 3 weeks,2 cycles).
After completion of chemoradiotherapy, PD-1 antibody was given continuously with 2-4 cycles of chemotherapy (the same regimen with concurrent chemotherapy) until 1 year or desease progression.
|
200mg, d1, q3W
50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
150mg/m2, d1, q3W
75mg/m2, d1, q3W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Locoregional control rate
Time Frame: 3 year
|
3 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiomics analysis
Time Frame: 1 year, 2 year, 3 year, 5 year
|
Analysis of correlation between radiomics signature extracted by LASSO and the rate of participants who achieve pathological complete response (pCR) and the overall survival based on MRI and CT simulation.
|
1 year, 2 year, 3 year, 5 year
|
Number of participants with acute toxicities
Time Frame: 10 week, from the start of treatment to 1 month after chemoradiotherapy
|
Acute toxicities are evaluated by NCI-CTC version 5.0
|
10 week, from the start of treatment to 1 month after chemoradiotherapy
|
Tumor response rate
Time Frame: 2-3 months
|
2-3 months
|
|
Progression free survival
Time Frame: 1 year, 2 year, 3 year
|
1 year, 2 year, 3 year
|
|
Overall survival
Time Frame: 1 year, 2 year, 3 year
|
1 year, 2 year, 3 year
|
|
Objective response rate
Time Frame: 5.5 week
|
Objective Response Rate are evaluated by RECIST 1.1
|
5.5 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2020
Primary Completion (Anticipated)
September 30, 2023
Study Completion (Anticipated)
September 30, 2023
Study Registration Dates
First Submitted
March 15, 2021
First Submitted That Met QC Criteria
March 26, 2021
First Posted (Actual)
March 30, 2021
Study Record Updates
Last Update Posted (Actual)
March 30, 2021
Last Update Submitted That Met QC Criteria
March 26, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Antibodies
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- NCC2749
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oligometastatic Disease
-
Steven BurtonTerminatedOligometastatic DiseaseUnited States
-
Istituto Clinico HumanitasNot yet recruiting
-
National Cancer Institute, NaplesRecruiting
-
IRCCS San RaffaeleRecruitingOligometastatic DiseaseItaly
-
Steven BurtonCompletedRecurrent Oligometastatic DiseaseUnited States
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedSolid Tumors With Oligometastatic SpreadCanada
-
Katelyn AtkinsNot yet recruitingOligometastatic DiseaseUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Not yet recruitingPancreatic Ductal Adenocarcinoma | Oligometastatic DiseaseUnited States
-
ImmuneSensor Therapeutics Inc.RecruitingOligometastatic DiseaseUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI); Bracco Diagnostics, IncRecruitingColorectal Cancer | Liver Metastases | Oligometastatic DiseaseUnited States
Clinical Trials on PD-1 antibody
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsRecruitingNasopharyngeal Carcinoma | Surgery | PD-1China
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.Completed
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingNasopharyngeal Carcinoma
-
Henlix, IncUnknown
-
Sun Yat-sen UniversityRecruitingColorectal Cancer Metastatic | MSSChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingExtensive Stage Small Cell Lung Cancer